Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

2.

The search for safer glucocorticoid receptor ligands.

Rosen J, Miner JN.

Endocr Rev. 2005 May;26(3):452-64. Epub 2005 Apr 6. Review.

PMID:
15814846
3.

Ligand-specific dynamics of the progesterone receptor in living cells and during chromatin remodeling in vitro.

Rayasam GV, Elbi C, Walker DA, Wolford R, Fletcher TM, Edwards DP, Hager GL.

Mol Cell Biol. 2005 Mar;25(6):2406-18.

4.

Dexamethasone suppresses eNOS and CAT-1 and induces oxidative stress in mouse resistance arterioles.

Schäfer SC, Wallerath T, Closs EI, Schmidt C, Schwarz PM, Förstermann U, Lehr HA.

Am J Physiol Heart Circ Physiol. 2005 Jan;288(1):H436-44. Erratum in: Am J Physiol Heart Circ Physiol. 2005 Dec;289(6):H2752.

5.

Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid receptor target genes.

Wang JC, Derynck MK, Nonaka DF, Khodabakhsh DB, Haqq C, Yamamoto KR.

Proc Natl Acad Sci U S A. 2004 Nov 2;101(44):15603-8. Epub 2004 Oct 22.

6.

Design and evaluation of novel nonsteroidal dissociating glucocorticoid receptor ligands.

Shah N, Scanlan TS.

Bioorg Med Chem Lett. 2004 Oct 18;14(20):5199-203.

PMID:
15380227
7.

One nucleotide in a kappaB site can determine cofactor specificity for NF-kappaB dimers.

Leung TH, Hoffmann A, Baltimore D.

Cell. 2004 Aug 20;118(4):453-64.

8.

Gene expression profiling of glucocorticoid-inhibited osteoblasts.

Leclerc N, Luppen CA, Ho VV, Nagpal S, Hacia JG, Smith E, Frenkel B.

J Mol Endocrinol. 2004 Aug;33(1):175-93.

PMID:
15291752
9.
10.

Dexamethasone lacks effect on blood pressure in mice with a disrupted endothelial NO synthase gene.

Wallerath T, Gödecke A, Molojavyi A, Li H, Schrader J, Förstermann U.

Nitric Oxide. 2004 Feb;10(1):36-41.

PMID:
15050533
11.

Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta.

Tee MK, Rogatsky I, Tzagarakis-Foster C, Cvoro A, An J, Christy RJ, Yamamoto KR, Leitman DC.

Mol Biol Cell. 2004 Mar;15(3):1262-72. Epub 2003 Dec 29.

12.

Target-specific utilization of transcriptional regulatory surfaces by the glucocorticoid receptor.

Rogatsky I, Wang JC, Derynck MK, Nonaka DF, Khodabakhsh DB, Haqq CM, Darimont BD, Garabedian MJ, Yamamoto KR.

Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13845-50. Epub 2003 Nov 14.

13.

p38 MAP kinase signalling is required for hypertrophic chondrocyte differentiation.

Stanton LA, Sabari S, Sampaio AV, Underhill TM, Beier F.

Biochem J. 2004 Feb 15;378(Pt 1):53-62.

14.

Brief bone morphogenetic protein 2 treatment of glucocorticoid-inhibited MC3T3-E1 osteoblasts rescues commitment-associated cell cycle and mineralization without alteration of Runx2.

Luppen CA, Leclerc N, Noh T, Barski A, Khokhar A, Boskey AL, Smith E, Frenkel B.

J Biol Chem. 2003 Nov 7;278(45):44995-5003. Epub 2003 Aug 20.

15.

Identification of a functional glucocorticoid response element in the promoter of the cyclin-dependent kinase inhibitor p57Kip2.

Alheim K, Corness J, Samuelsson MK, Bladh LG, Murata T, Nilsson T, Okret S.

J Mol Endocrinol. 2003 Jun;30(3):359-68.

PMID:
12790805
16.

A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR.

Downes M, Verdecia MA, Roecker AJ, Hughes R, Hogenesch JB, Kast-Woelbern HR, Bowman ME, Ferrer JL, Anisfeld AM, Edwards PA, Rosenfeld JM, Alvarez JG, Noel JP, Nicolaou KC, Evans RM.

Mol Cell. 2003 Apr;11(4):1079-92.

17.

Human mesenchymal stem cells as an in vitro model for human adipogenesis.

Janderová L, McNeil M, Murrell AN, Mynatt RL, Smith SR.

Obes Res. 2003 Jan;11(1):65-74.

18.

The annexin-1 knockout mouse: what it tells us about the inflammatory response.

Roviezzo F, Getting SJ, Paul-Clark MJ, Yona S, Gavins FN, Perretti M, Hannon R, Croxtall JD, Buckingham JC, Flower RJ.

J Physiol Pharmacol. 2002 Dec;53(4 Pt 1):541-53. Review.

19.

Mechanisms involved in the side effects of glucocorticoids.

Schäcke H, Döcke WD, Asadullah K.

Pharmacol Ther. 2002 Oct;96(1):23-43. Review.

PMID:
12441176
20.

Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor.

Perretti M, Chiang N, La M, Fierro IM, Marullo S, Getting SJ, Solito E, Serhan CN.

Nat Med. 2002 Nov;8(11):1296-302. Epub 2002 Oct 7.

Supplemental Content

Support Center